4//SEC Filing
Babu Yarlagadda S 4
Accession 0001127602-22-025761
CIK 0000882796other
Filed
Nov 15, 7:00 PM ET
Accepted
Nov 16, 4:19 PM ET
Size
12.1 KB
Accession
0001127602-22-025761
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Sale
Common Stock
2022-11-14$13.88/sh−31,515$437,428→ 298,541 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2022-11-14−50,000→ 0 totalExercise: $1.42From: 2014-01-01Exp: 2023-01-01→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2022-11-14$1.42/sh+50,000$71,000→ 280,056 total - Exercise/Conversion
Common Stock
2022-11-14$1.42/sh+50,000$71,000→ 330,056 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2022-11-14−50,000→ 0 totalExercise: $1.42From: 2014-01-01Exp: 2023-01-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F2]Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
- [F3]Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001452635
Filing Metadata
- Form type
- 4
- Filed
- Nov 15, 7:00 PM ET
- Accepted
- Nov 16, 4:19 PM ET
- Size
- 12.1 KB